FDA approves first treatment for adults with complement 3 glomerulopathy, a rare kidney disease, to reduce proteinuria

The U.S. Food and Drug Administration has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G) to reduce proteinuria.